EPO and chronic kidney disease: The major cause of anemia associated with CKD is decreased production of erythropoietin by the kidneys, and this type of anemia can be treated with erythropoiesis-stimulating agents and hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors by increasing the production of endogenous erythropoietin through treatment.